SERA vs. CDNA, CELC, CSTL, FLGT, BDSX, LUCD, CODX, TLIS, VRDN, and VCYT
Should you be buying Sera Prognostics stock or one of its competitors? The main competitors of Sera Prognostics include CareDx (CDNA), Celcuity (CELC), Castle Biosciences (CSTL), Fulgent Genetics (FLGT), Biodesix (BDSX), Lucid Diagnostics (LUCD), Co-Diagnostics (CODX), Talis Biomedical (TLIS), Viridian Therapeutics (VRDN), and Veracyte (VCYT). These companies are all part of the "medical" sector.
CareDx (NASDAQ:CDNA) and Sera Prognostics (NASDAQ:SERA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, community ranking, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.
54.6% of Sera Prognostics shares are owned by institutional investors. 4.2% of CareDx shares are owned by insiders. Comparatively, 15.8% of Sera Prognostics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
CareDx has a beta of 1.51, meaning that its stock price is 51% more volatile than the S&P 500. Comparatively, Sera Prognostics has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500.
In the previous week, Sera Prognostics had 1 more articles in the media than CareDx. MarketBeat recorded 6 mentions for Sera Prognostics and 5 mentions for CareDx. Sera Prognostics' average media sentiment score of 0.65 beat CareDx's score of 0.00 indicating that CareDx is being referred to more favorably in the media.
CareDx has a net margin of -67.88% compared to CareDx's net margin of -11,843.79%. CareDx's return on equity of -45.74% beat Sera Prognostics' return on equity.
Sera Prognostics has lower revenue, but higher earnings than CareDx. Sera Prognostics is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks.
CareDx currently has a consensus target price of $14.00, suggesting a potential upside of 27.50%. Sera Prognostics has a consensus target price of $2.75, suggesting a potential downside of 72.72%. Given Sera Prognostics' stronger consensus rating and higher possible upside, equities analysts clearly believe CareDx is more favorable than Sera Prognostics.
CareDx received 414 more outperform votes than Sera Prognostics when rated by MarketBeat users. Likewise, 66.61% of users gave CareDx an outperform vote while only 36.00% of users gave Sera Prognostics an outperform vote.
Summary
CareDx beats Sera Prognostics on 10 of the 18 factors compared between the two stocks.
Get Sera Prognostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SERA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SERA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sera Prognostics Competitors List
Related Companies and Tools
